Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$519MCash, Jun 2026
21moCash Runway (est.)
+3%Share Count, 1 Year
Follow KURA by emailGet an email when KURA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KURA, unsubscribe in one click. Privacy
📣 What KURA Says Is Next
in 2028 · “Combined with $180 million in anticipated collaboration payments from Kyowa Kirin, the Company believes its current cash resources will be sufficient to fund the ziftomenib AML program through the topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028.”
Company press release, Aug 12, 2026 · SEC filing
in 2028 · “The Company believes its cash, cash equivalents and short-term investments as of March 31, 2026, when combined with $180 million in anticipated payments under the collaboration agreement with Kyowa Kirin, will be sufficient to fund the ziftomenib AML program through the topline results from the first pivotal Phase 3 KOMET-017 frontline trial, anticipated in 2028.”
Company press release, May 12, 2026 · SEC filing
in 2026 · “FIT-001 Phase 1b dose expansion : Enrollment is ongoing 2026 Commercial Priorities and Anticipated Development Milestones Kura expects multiple value-driving catalysts in 2026 across commercial development and clinical development: KOMZIFTI Commercial Execution”
Company press release, May 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
KURA reported $519M in cash and short-term investments (as of Jun 30, 2026) and used about $74.8M/quarter in operations, an estimated runway of 20.8 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KURA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.